Evolving Challenges in Closed-System Biomanufacturing

Optibumin vs Traditional Albumin: Comparing Performance in Cell Wash Applications

Scaling Innovation: How DiscGenics and InVitria are Leading the Future of Cell Therapy

Solving the Vaccine Supply Challenge

SARS-CoV2 and Influenza – Double Threat

High-Performance Production of Viral Vectors for Cell and Gene Therapy Using OptiPEAK HEK293t Complete Media

Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease

Controlling Impurities in Cell Culture Media

BioInnovation on Parade: Philly Stands Proud for BIO 2019!

Explore the Latest Developments in T-reg Research and Clinical Application

Exploring the Latest Research and Opportunities in T-reg Therapy

ASGCT 2019: Remarkable Milestones and Achievements in Cell and Gene Therapy

Recombinant Albumin for Stabilization of Live-Attenuated Viral Vaccines

Universal Vaccine Against Seasonal Influenza Steps Closer to Reality with the Results of FluGen Phase 2 Clinical Trial

ECI Conference 2019: The Latest Innovations and Trends in Cell & Gene Therapy

Phacilitate 2019 and World Stem Cell Summit

Join InVitria at ECI 2019

Join InVitria at Phacilitate 2019

Happy Holidays from the InVitria Team!

BIO Europe 2018: From Lab Innovations to Commercial Realities

InVitria Expands Operations to Anschutz Medical Campus in the Denver Metro Area

BIO 2018: The Emergence of Gene & Cell Therapy

InVitria at the American Association of Immunologists 2018 Conference

InVitria’s Top Insights from ISCT 2018 – Montreal

3 Takeaways from the World Vaccine Congress 2018